ChemoCentryx, Inc. (Nasdaq: CCXI) to Ring The Nasdaq Stock Market Closing Bell Remotely from the Nasdaq Entrepreneurial Cente...
January 20 2017 - 10:00AM
What: ChemoCentryx, Inc. (Nasdaq:CCXI), a
clinical-stage biopharmaceutical company focused on discovering,
developing and commercializing orally-administered therapeutics
that target the chemokine and chemoattractant systems in order to
treat autoimmune diseases, inflammatory disorders and cancer, will
visit the Nasdaq Entrepreneurial Center in San Francisco.
In honor of the occasion, Thomas J. Schall, Ph.D.,
President, Chief Executive Officer and Chairman of the
Board, will ring the Closing Bell.
Where:Nasdaq Entrepreneurial Center – 505
Howard Street, San Francisco, CA
When:Monday, January 23, 2017 – 3:45 p.m. to
4:00 p.m. ET
ChemoCentryx Contact:Susan M.
Kanaya650-210-2900investor@chemocentryx.com
Nasdaq MarketSite:Emily Pan(646)
441-5120emily.pan@nasdaq.com
Feed Information:Fiber Line (Encompass
Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:For multimedia features such as
exclusive content, photo postings, status updates and video of bell
ceremonies, please visit our Facebook
page:http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our
Instagram page:http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our
YouTube page:http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter
page:http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our
Tumblr page:http://nasdaq.tumblr.com/
Webcast: A live stream of the Nasdaq Closing
Bell will be available at: https://new.livestream.com/nasdaq/live
or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of
the Market Close, please go to
http://business.nasdaq.com/discover/market-bell-ceremonies and
click on the market close of your choice.
About ChemoCentryxChemoCentryx, Inc. is a
clinical-stage biopharmaceutical company focused on discovering,
developing and commercializing orally-administered therapeutics
that target the chemokine and chemoattractant systems in order to
treat autoimmune diseases, inflammatory disorders and cancer. The
chemokine system is a biological network that regulates
inflammation via a collection of secreted chemokine molecules, or
ligands, and their specific cell surface receptors. Based on its
proprietary drug discovery and drug development
platform, ChemoCentryx has generated multiple clinical
and preclinical-stage programs, each targeting distinct chemokine
and chemoattractant receptors with different small molecule
compounds. Avacopan (CCX168), a C5aR inhibitor, is in Phase III
development for the treatment of anti-neutrophil cytoplasmic
auto-antibody-associated vasculitis (AAV). Avacopan has
successfully completed Phase II development for the treatment of
AAV and appears to be safe, well tolerated and successful in
allowing reduction and elimination of high-dose steroids, part of
standard of care for AAV patients, while providing effective
control of the disease in clinical studies to date. Avacopan is
also in development for the treatment of atypical hemolytic uremic
syndrome (aHUS) and complement 3 glomerulopathy (C3G).
CCX140, an inhibitor of the chemokine receptor known as CCR2, which
has demonstrated significant reductions in proteinuria in patients
with diabetic nephropathy in a successfully completed Phase II
study, is currently focused on a rare kidney disease known as focal
segmental glomerulosclerosis (FSGS). Both avacopan and CCX140
are part of a Vifor Pharma-ChemoCentryx Kidney Health Alliance
which provides Vifor Pharma with exclusive rights to commercialize
avacopan and CCX140 in certain markets outside of the U.S.
CCX872, a distinct CCR2 inhibitor, successfully completed
Phase I development and is in development for the treatment of
non-resectable pancreatic cancer. Other clinical programs
include CCX507, a next generation CCR9 inhibitor, which has
successfully completed Phase I development, vercirnon (also known
as Traficet-EN or CCX282) a specific CCR9 inhibitor for the
treatment of inflammatory bowel disease, and CCX354, a CCR1
inhibitor which successfully completed a Phase II clinical trial
for the treatment of rheumatoid
arthritis. ChemoCentryx also has several programs in
advanced preclinical development.
About NasdaqNasdaq (Nasdaq:NDAQ) is a leading
provider of trading, clearing, exchange technology, listing,
information and public company services across six continents.
Through its diverse portfolio of solutions, Nasdaq enables
customers to plan, optimize and execute their business vision with
confidence, using proven technologies that provide transparency and
insight for navigating today's global capital markets. As the
creator of the world's first electronic stock market, its
technology powers more than 70 marketplaces in 50 countries, and 1
in 10 of the world's securities transactions. Nasdaq is home to
more than 3,700 listed companies with a market value of $10.0
trillion and approximately 18,000 corporate clients. To learn more,
visit: nasdaq.com/ambition or business.nasdaq.com
-NDAQA-
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Feb 2024 to Mar 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Mar 2023 to Mar 2024